Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

What Investors Need to Know About Oracle's Cloud Slowdown

SEC Filing – Royalty Pharma

S-1

S-1

SEC Filing – Royalty Pharma

SEC Filing – Royalty Pharma

S-1/A

March 2016 Baltimore Beacon by The Beacon Newspapers - Issuu

S-1

October, 2015

Amendment No. 1 to Draft Registration Statement

S-1

Is WeWork bouncing back? Shared office space company reaches $228 million in revenue in September

There's A Dark Cloud On Dropbox's Horizon

Vertex Pharmaceuticals' Revenue by Product (2016-2023)